SELLAS Life Sciences Group, Inc.
SLS
$1.41
$0.010.71%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -2.49% | -9.50% | -0.74% | 4.57% | 10.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -13.88% | -16.27% | -5.74% | -0.72% | 14.93% |
| Operating Income | 13.88% | 16.27% | 5.74% | 0.72% | -18.53% |
| Income Before Tax | 17.30% | 15.77% | 4.55% | -0.43% | 9.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 17.30% | 15.77% | 4.55% | -0.43% | 9.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 17.30% | 15.77% | 4.55% | -0.43% | 9.59% |
| EBIT | 13.88% | 16.27% | 5.74% | 0.72% | -18.53% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 60.82% | 54.07% | 40.26% | 33.02% | 38.89% |
| Normalized Basic EPS | 59.75% | 54.31% | 40.59% | 33.58% | 15.89% |
| EPS Diluted | 60.79% | 54.05% | 40.23% | 33.02% | 38.89% |
| Normalized Diluted EPS | 59.75% | 54.31% | 40.59% | 33.58% | 15.89% |
| Average Basic Shares Outstanding | 120.33% | 99.44% | 73.31% | 55.34% | 43.24% |
| Average Diluted Shares Outstanding | 120.33% | 99.44% | 73.31% | 55.34% | 43.24% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |